Mount Sinai Hospital, Chicago, IL
Professional Role and Affiliations:
Dr. Haoliang Xu currently serves as an Attending Pathologist at Mount Sinai Hospital located at 1500 S Fairfield Ave, Chicago, IL 60608. He holds significant leadership roles including Medical Director of Anatomic Pathology since March 2022 and Medical Director of the Laboratory Compliance and FDA-Regulated Activities at Mount Sinai. He has held the position of attending pathologist at Sinai Chicago since August 2021 and is also noted as Medical Director of Holy Cross Hospital since December 2022, indicating his extended professional engagement within the broader hospital system.
His contact telephone numbers are publicly listed as (773) 257-5056 for direct clinical services and (773) 542-2000 for the hospital main line.
Educational Background and Credentials:
Dr. Xu earned his medical degree and completed relevant pathology training, with noted associations to Northwestern University for his education. He holds the degrees MD and PhD. According to the American Board of Pathology’s 2021 Annual Report, he is board-certified in Anatomic Pathology and Clinical Pathology disciplines.
Institutional Context and Reputation:
Mount Sinai Hospital is a part of the Sinai Health System in Chicago, consistently recognized for clinical quality and safety excellence, often referenced in Newsweek's rankings for top hospitals both nationally and globally. The institution emphasizes cutting-edge healthcare delivery and research, with strong integration between clinical departments and academic research. Dr. Xu's affiliation with this system positions him within a high-performing clinical and research environment.
Research and Academic Contributions:
Dr. Xu is a Fellow alumnus of Washington University in St. Louis with a record of publishing over 40 peer-reviewed articles, cited over 500 times. His research focuses notably on pathology, autoimmune disease mechanisms, and clinical applications in oncology and hematopathology. Although specific recent publications directly authored by Dr. Xu at Mount Sinai are not explicitly listed, he is tied to multiple publications affiliated with Sinai Health System, Icahn School of Medicine at Mount Sinai (New York), and Chicago hospitals. He has co-authored work related to diagnostic pathology, including immunohistochemistry (ERBB4 and RB1 biomarkers) to distinguish renal carcinomas, brain injury studies, and clinical case reports.
His involvement in the College of American Pathologists Annual Meeting highlights active participation in professional clinical pathology communities. Moreover, Dr. Xu contributes to translational research at Mount Sinai that intersects with molecular mechanisms such as the PTEN/mTOR signaling pathway in axons.
Clinical and Operational Expertise:
As Medical Director of Anatomic Pathology and Laboratory Compliance at Mount Sinai Hospital, Dr. Xu is responsible for overseeing laboratory operations, ensuring regulatory compliance (including FDA regulation adherence), and guiding pathology diagnostic services. This operational leadership underscores his role in maintaining clinical quality and integrity within the hospital’s pathology laboratory services.
His clinical expertise includes specialties in Anatomic Pathology, Clinical Pathology, and Hematopathology, supporting diagnosis and treatment guidance in oncology and general pathology. His multidisciplinary reach extends to supportive oncology and survivorship care initiatives, as indicated by collaborations on cancer supportive care projects.
Professional Network and Visibility:
Dr. Xu maintains an active professional network with over 130 LinkedIn connections, primarily comprising medical professionals and researchers. His online profiles confirm a male physician fluent in English, actively practicing in Chicago.
Institutional Impact and Initiatives:
Mount Sinai Hospital’s participation in global healthcare quality forums, including showcasing safety and quality practices internationally (e.g., Singapore Forum, 2025), aligns with Dr. Xu’s institutional environment. Although no direct personal media releases or highlighted achievements were found, his senior medical roles and leadership in pathology position him centrally in hospital initiatives to elevate clinical laboratory standards and patient outcomes.
This comprehensive profile of Dr. Haoliang Xu reflects a highly qualified, research-active medical director and attending pathologist embedded in a major academic hospital with broad clinical and operational responsibilities. His leadership roles in pathology and laboratory compliance suggest a key influence on clinical diagnostic practices and regulatory adherence at Mount Sinai Hospital, making him a pivotal contact within the institution’s pathology and laboratory services.
